Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.43 |
| ▸ | JAK1 | P23458 | 3/20 | 0.43 |
| ▸ | TYK2 | P29597 | 3/20 | 0.43 |
| ▸ | JAK3 | P52333 | 3/20 | 0.43 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27201403 | 0.83 | JAK2 (0.51) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL3312540 | 0.72 | ALDH1A1 (0.62) | PROKR1ALDH1A1HSD11B1HPGDLMNA | |
| SCHEMBL27201606 | 0.71 | CHRM1 (0.41) | JAK2JAK1JAK3 | |
| SCHEMBL27201362 | 0.71 | HRH4 (0.42) | LMNA | |
| SCHEMBL6347014 | 0.70 | HSD11B1 (0.53) | PROKR1PDE2APDE3AHSD11B1DRD4 | |
| SCHEMBL27201472 | 0.70 | HDAC4 (0.48) | PDE2APDE3AHSD11B1 | |
| SCHEMBL28773886 | 0.68 | DDB1 (0.45) | PROKR1ALDH1A1PDE2APDE3AHSD11B1 | |
| SCHEMBL31215226 | 0.68 | JAK2 (0.38) | JAK2JAK1TYK2JAK3HSD11B1 | |
| SCHEMBL13490412 | 0.67 | KDM5A (0.54) | ALDH1A1HSD11B1HPGD | |
| SCHEMBL27984145 | 0.66 | MYC (0.47) | PROKR1ALDH1A1HSD11B1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | GID4, MDM2, XIAP | JAK2 1493/4885JAK1 2614/4885TYK2 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.